Plaque Psoriasis Treatment Market Size, Share, Growth, and Outlook (2024-2031)

Global Plaque Psoriasis Treatment Market is segmented By Disease Type (Small-Plaque Psoriasis, Large-Plaque Psoriasis, Unstable Plaque Psoriasis, Chronic Plaque Psoriasis), By Treatment Type (Topical Medications, Systemic Drugs, Biologics, Phototherapy, Others), By Sales Channel (Distribution Channel, End-User), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Plaque Psoriasis Treatment Market Overview

The Global plaque psoriasis treatment market is expected to reach at a high CAGR during the forecast period 2023-2030.

Plaque psoriasis also known as psoriasis vulgaris is a long-lasting and chronic autoimmune skin disease that causes cells to reproduce very quickly. It’s the most common type of psoriasis that causes thick, scaly patches called plaques on the skin. Typically, new skin cells grow every 28 to 30 days. But in the case of plaque psoriasis, new cells grow and move to the skin's surface every three to four days. The buildup of new cells replacing old cells creates plaques.

Moreover, plaque psoriasis isn’t contagious. There is no cure for plaque psoriasis, but many treatment options are available, depending on the individual and the severity of symptoms. Topical therapy includes the use of emollients and moisturizers, corticosteroids, keratolytics, coal tar, anthralin, vitamin D3 analogs and calcineurin inhibitors. A combination of topical agents is sometimes more effective than when the drugs are used alone. Phototherapy is also most commonly used in the treatment.

Plaque Psoriasis Treatment Market Scope

To Know More Insights - Download Sample

Plaque Psoriasis Treatment Market Dynamics

Increasing adoption of innovative medications

The increasing adoption of innovative medications for plaque psoriasis is expected to drive the market over the forecast period. The development of innovative medications aims to address unmet needs and results in better disease management. In recent years, biosimilars are most focused in the treatment of plaque psoriasis, because biosimilars offers a wide range of benefits and require much less research and development than their reference biologics. Biosimilars are much cheaper to produce. 

For instance, on January 06, 2023, Alvotech and Teva Pharmaceuticals cleared that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application for AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab). STELARA (ustekinumab) is indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Moreover, many regulatory approvals such as FDA approvals increase the adoption of innovative medications by boosting the trust in patients about the safety of the medications. For instance, on September 09, 2022, Bristol Myers Squibb released that the U.S. Food and Drug Administration (FDA) approved Sotyktu(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Additionally, on June 1, 2021, Novartis, a leader in immuno-dermatology and rheumatology, cleared the U.S. Food and Drug Administration (FDA) approval of Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the US. 

Further, the increasing prevalence of plaque psoriasis, rising regulatory approvals, increasing clinical trials for advanced therapies, increasing awareness and early detection and technological advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the high doses of topical corticosteroids and other drugs,  the high cost of the treatment phototherapy and the lack of better and accurate treatment are expected to hamper the market. 

Plaque Psoriasis Treatment Market Segment Analysis

The global plaque psoriasis treatment market is segmented based on disease type, treatment type, sales channel and region.

The topical medications segment accounted for approximately 41.1% of the plaque psoriasis treatment market share

The topical medications segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for plaque psoriasis, but topical medications are considered first-line therapeutics based on the severity and symptoms. Various types of topical medications such as anthralin, roflumilast (zoryve), corticosteroids, tapinarof (VTAMA), salicylic acid, coal tar, zinc pyrithione  and topical emollients are most commonly used for the treatment. 

For instance, on May 24, 2022, Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, cleared the U.S. Food and Drug Administration (FDA) approval of VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.

Moreover, on July 29, 2022, Arcutis Biotherapeutics, Inc. cleared the U.S. Food and Drug Administration (FDA) approval of the New Drug Application for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis, ZORYVE provides rapid clearance of psoriasis plaques and reduces itch in all affected areas of the body.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. The topical medications manage skin symptoms and have anti-inflammatory effects on the skin to clear psoriasis plaques. They include a class of medication called a corticosteroid. Although they are effective and fast-acting for better patient outcomes. In addition, their wide adoption also increases the demand for topical medications. 

Plaque Psoriasis Treatment Market Geographical Share

North America accounted for approximately 40.1% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of novel medications. North America especially in the United States has a strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. This presence of major players actively performs in research activities for the development of more advanced and effective therapeutics for the treatment of plaque psoriasis.

For instance, on December 20, 2021, Amgen released the U.S. Food and Drug Administration (FDA) approval of Otezla (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate and severe.

Furthermore, due to the increasing prevalence of the condition, there is an increasing adoption of novel medications in the region. For instance, according to the National Psoriasis Foundation/USA, more than 8 million people in the U.S. have psoriasis. About eight in 10 people with psoriasis have plaque psoriasis. The increasing prevalence is increasing the demand for the adoption of novel therapeutics for the early management of the condition and associated severity for the better patient outcomes.

Plaque Psoriasis Treatment Market Companies

The major global players in the plaque psoriasis treatment market include Dermavant Sciences, Inc., Novartis AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca PLC, Lupin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, AbbVie Inc., Eli Lilly and Company and among others. 

Key Developments

• On May 28, 2022, UCB announced cleared the U.S. Food and Drug Administration (FDA) approval of extending the label for CIMZIA (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis. CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. The approval makes CIMZIA the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks the entry of UCB into immuno-dermatology, where a significant unmet need currently exists. 
• On May 25, 2022, Almirall S.A. launched Wynzora cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate), developed for the topical treatment of mild to moderate plaque psoriasis in adults including scalp.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global plaque psoriasis treatment market. During the pandemic, many clinical trials were delayed or temporarily halted due to the redirected focus on the COVID-19 pandemic. This could have affected the development and approval timelines for new treatments or drugs in plaque psoriasis. The pandemic accelerated the adoption of telehealth services. Dermatologists and healthcare providers started offering virtual consultations, which could have influenced patients with plaque psoriasis to receive care and prescriptions. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global plaque psoriasis treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of plaque psoriasis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global plaque psoriasis treatment market report would provide approximately 61 tables, 59 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies